MedPath

Ibuprofen Versus Placebo For Muscle Soreness

Phase 4
Completed
Conditions
Muscle Soreness
Interventions
Registration Number
NCT03228992
Lead Sponsor
Jean Brown Research
Brief Summary

The study will assess the sensitivity of the Delayed Onset Muscle Soreness Model by comparing the safety and efficacy of oral ibuprofen to placebo over 24 hours.

Detailed Description

This is a double-blind, randomized, placebo controlled, parallel group, pilot safety and efficacy study. Healthy male or female subjects who have a history of occasional muscle soreness and are not currently exercising will be asked to volunteer for the study. All subjects will complete an informed consent process prior to study procedures.

The study duration is anticipated to be approximately 4 months. Each subject may be in the study for up to 45 days including screening, run-in, inpatient and outpatient dosing and assessments, follow-up visit and follow-up telephone contact.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
31
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
IbuprofenIbuprofen 400 mgSubjects will receive a total of 4 doses of oral ibuprofen 400 mg over a 24 hour period.
PlaceboPlaceboSubjects will receive a total of 4 doses of oral placebo over a 24 hour period.
Primary Outcome Measures
NameTimeMethod
Model Sensitivity24 hours

Assess whether ibuprofen provides more relief than placebo in the DOMS model.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Jean Brown Research

🇺🇸

Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath